73,253 Shares in Novo Nordisk A/S $NVO Bought by Capital Investment Counsel LLC

Key Points

• Capital Investment Counsel LLC opened a new position in Novo Nordisk, acquiring 73,253 shares in the fourth quarter valued at about $3.73 million.
• Novo will begin shipping the oral Ozempic (semaglutide) tablets in the U.S. on May 4, a launch supported by FDA moves to restrict GLP‑1 compounding and distribution wins (WeightWatchers Med+, GoodRx) that should help uptake and protect branded volumes.
• The stock faces mounting competitive and pricing risks — Canada approved a second generic semaglutide and Eli Lilly’s oral GLP‑1 rollout increases pressure — and analysts have trimmed ratings, with a consensus target of roughly $65.56 versus a recent share price near $43.84.

Capital Investment Counsel LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 73,253 shares of the company's stock, valued at approximately $3,727,000.

Several other large investors have also modified their holdings of the company. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Novo Nordisk A/S by 5.7% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 168,145 shares of the company's stock worth $8,555,000 after buying an additional 9,100 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Novo Nordisk A/S by 2.4% during the 4th quarter. Fifth Third Bancorp now owns 42,160 shares of the company's stock worth $2,145,000 after buying an additional 978 shares during the period. Danske Bank A S bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $509,000. Mutual Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 2.0% during the 4th quarter. Mutual Advisors LLC now owns 48,523 shares of the company's stock worth $2,469,000 after buying an additional 933 shares during the period. Finally, Oppenheimer & Co. Inc. boosted its holdings in shares of Novo Nordisk A/S by 1.0% during the 4th quarter. Oppenheimer & Co. Inc. now owns 234,842 shares of the company's stock worth $11,949,000 after buying an additional 2,277 shares during the period. 11.54% of the stock is owned by institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA moves to restrict mass compounding of GLP‑1 active ingredients, which would make it harder for copycat/compounded alternatives to scale and should help protect branded pricing and volumes. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Novo will start shipping its oral Ozempic (semaglutide) tablets in the U.S. on May 4, expanding its addressable market beyond injectables and helping defend diabetes sales as pricing pressure mounts. Ozempic pill available in US
• Positive Sentiment: Distribution/access wins (WeightWatchers Med+ and GoodRx adding the Ozempic pill) should support uptake and patient access for the oral launch. WeightWatchers expands access to Ozempic pill
• Neutral Sentiment: Analysts’ consensus still shows material upside vs. the current price (average target ~$65.56) and small EPS estimate tweaks from Erste Group — supportive context but not immediate drivers. Analyst price targets
• Negative Sentiment: Canada approved a second generic semaglutide (Apotex), signaling increasing global generic competition that could undercut Novo’s pricing and margins in core markets over time. Canada approves second generic version of Ozempic
• Negative Sentiment: Eli Lilly’s Q1 beat, raised guidance and approval/rollout of Foundayo (an easier-to-take oral GLP‑1) widen competitive pressure on Novo’s weight‑loss franchise and could lead to share loss. Lilly's Double-Beat Widens the GLP-1 Gap
• Negative Sentiment: Ongoing concerns around pricing pressure and margin compression in the GLP‑1 market could make NVO’s recent rebound vulnerable if generics and convenience-focused rivals keep gaining traction. Pricing pressure and falling margins analysis

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. TD Cowen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price objective for the company. in a report on Tuesday, March 10th. BMO Capital Markets reissued a "market perform" rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a "peer perform" rating for the company. Weiss Ratings downgraded shares of Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, April 22nd. Finally, Citigroup initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a "neutral" rating for the company. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $65.56.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $43.84 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The firm has a fifty day moving average price of $38.50 and a two-hundred day moving average price of $47.33. The company has a market cap of $195.76 billion, a PE ratio of 12.64, a price-to-earnings-growth ratio of 10.02 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Analysts expect that Novo Nordisk A/S will post 3.34 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were issued a dividend of $1.2751 per share. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 50.43%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.